Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: Cambridge Biotech

This article was originally published in The Gray Sheet

Executive Summary

Cambridge Biotech: Agrees to sell its enteric product line to Meridian Diagnostics for $5.5 mil. cash plus a $200,000 advance payment in royalties and other considerations. Meridian's counterbid offer, which topped a previously announced $4.5 mil. agreement with Carter-Wallace ("The Gray Sheet" May 13, In Brief), was approved by the U.S. Bankruptcy Court, which is overseeing Cambridge's reorganization under Chapter 11 of the bankruptcy code. Through the reorganization plan, Cambridge is selling its diagnostic businesses to focus entirely on "therapeutic and prophylactic vaccines for infectious diseases, and immunotherapeutics for cancer," the firm says. A hearing is planned to select a "winning bid" for Cambridge's retroviral business, for which a $6.5 mil. sale agreement to bioMerieux Vitek was announced in April. Interested parties had until June 11 to submit counterbids for the retroviral business. The U.S. Bankruptcy Court will review Cambridge's overall restructuring plan at a July 15, 1996 hearing...



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts